MDxHealth (MDXH)
NASDAQ:MDXH
Want to see MDXH full AI Analyst Report?
MDXH Stock Chart & Stats
$2.31
-$0.10(-4.55%)
At close: 4:00 PM EST
$2.31
-$0.10(-4.55%)
Day’s Range― - ―
52-Week Range$0.68 - $5.33
Previous CloseN/A
Volume27.23K
Average Volume (3M)194.90K
Market Cap
$45.87M
Enterprise Value$111.95M
Total Cash (Recent Filing)$29.03M
Total Debt (Recent Filing)$95.11M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Aug 20, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding51,364,520
10 Day Avg. Volume253,010
30 Day Avg. Volume194,899
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)-14.77
Price to Sales (P/S)1.66
P/FCF Ratio-15.43
Enterprise Value/Market Cap2.44
Enterprise Value/Revenue1.38
Enterprise Value/Gross Profit2.39
Enterprise Value/Ebitda-18.28
Forecast
1Y Price Target
$3.09Price Target Upside33.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.39
Revenue Forecast (FY)$138.28M
Bulls Say, Bears Say
Bulls Say
Clinical Study CatalystsFavorable outcomes from the GPS‑ProMPT study and collaboration to test GPS in the ProtecT trial could strengthen guideline support for active surveillance and increase clinical adoption of the GPS test.
Commercial Refocus And Product MixA redeployed sales force concentrating on higher‑return diagnostics and an appropriate test menu can accelerate commercial traction and raise revenue per customer.
Financial Structure And Cost DisciplineAmended earnout terms together with operating expense discipline improve near‑term liquidity and support progress toward sustainable profitability and positive free cash flow.
Bears Say
Acquisition‑related Expense PressureHigher headcount and acquisition‑related expenses reduced adjusted EBITDA versus expectations, highlighting margin pressure while integration completes.
Integration And Timing DisruptionTiming and integration challenges related to recent acquisitions produced a revenue shortfall, signaling execution risks that could pressure near‑term growth expectations.
Product Prioritization RiskDeprioritizing select legacy products led to a sales shortfall, exposing the risk that strategic shifts in the product mix may temporarily undermine top‑line growth.
MDxHealth News
MDXH FAQ
What was MDxHealth’s price range in the past 12 months?
MDxHealth lowest stock price was $0.68 and its highest was $5.33 in the past 12 months.
What is MDxHealth’s market cap?
MDxHealth’s market cap is $45.87M.
When is MDxHealth’s upcoming earnings report date?
MDxHealth’s upcoming earnings report date is Aug 20, 2026 which is in 95 days.
How were MDxHealth’s earnings last quarter?
MDxHealth released its earnings results on May 13, 2026. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.145 by -$0.045.
Is MDxHealth overvalued?
According to Wall Street analysts MDxHealth’s price is currently Undervalued.
Does MDxHealth pay dividends?
MDxHealth does not currently pay dividends.
What is MDxHealth’s EPS estimate?
MDxHealth’s EPS estimate is -0.17.
How many shares outstanding does MDxHealth have?
MDxHealth has 51,364,520 shares outstanding.
What happened to MDxHealth’s price movement after its last earnings report?
MDxHealth reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.145. Following the earnings report the stock price went down -49.538%.
Which hedge fund is a major shareholder of MDxHealth?
Currently, no hedge funds are holding shares in MDXH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MDxHealth Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.09 (33.77% Upside)
$3.09 (33.77% Upside)
Blogger Sentiment
Bullish
MDXH Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 28.4%
Last 30 Days ▲ 36.4%
Last 30 Days ▲ 36.4%
News Sentiment
Bullish
Bullish news 70%
Bearish news 30%
Bearish news 30%
Technicals
SMA
Negative
20 days / 200 days
Momentum
44.37%
12-Months-Change
Fundamentals
Return on Equity
516.59%
Trailing 12-Months
Asset Growth
-8.01%
Trailing 12-Months
Company Description
MDxHealth
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
MDXH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed but cautiously positive outlook: operationally the company is refocusing on its high-growth prostate cancer franchise with clear commercial integration wins (ExoDx transition, sales cross-training), AI initiatives, and a raised 2026 revenue target implying 20–26% growth. However, material near-term headwinds exist — most notably the strategic exit of the Resolve UTI business, a Novitas recoupment notice up to $10.4M, pro forma margin compression, and a wider operating loss driven by the ExoDx acquisition and integration — all of which create execution and liquidity considerations in the short term. Overall, management frames the Resolve exit as a proactive, value-accretive repositioning to prioritize scalable core growth while defending against payer recoupment risk.View all MDXH earnings summariesMDXH Stock 12 Month Forecast
Average Price Target
$3.09
▲(33.77% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.45% Mutual Funds
20.13% Other Institutional Investors
78.23% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---